Soolantra (IVermectin) Patent Expiration, LOE Window & CMS Spending

Soolantra (IVermectin) by Galderma Laboratories: FDA Orange Book LOE 2034-03-13, 3 AB generics, $1.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGalderma Laboratories
FDA Application & PathwayN206255 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-03-13
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$1.4M
2024 Medicaid Spend$21K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel